The preclinical data supports platform expansion potential but remains early-stage. Monitor for any future clinical trial announcements or partnership interest in epilepsy/neurology indications. No immediate change to the company's financial outlook.
Price Chart
Executive Summary
Kiora Pharmaceuticals announced preclinical data showing its ion channel modulator KIO-300 significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model (p<0.0001). The findings, presented at the Epilepsy Foundation Pipeline Conference, suggest potential pipeline expansion beyond ophthalmology, though no clinical development timeline was provided.
Key Facts
- KIO-300 produced sustained suppression of epileptiform activity in hippocampal CA1 slices from mice with induced temporal lobe epilepsy.
- Treatment reduced spontaneous epileptiform event frequency with statistically significant inhibition beginning 42 minutes after treatment (p<0.0001).
- KIO-300 did not impair broader electrical transmission, indicating specificity to abnormal activity.
- The suppressive effect persisted through both treatment and washout periods, suggesting prolonged neural tissue retention.
- KIO-300 is the active pharmaceutical ingredient of KIO-301, currently in Phase 2 for retinitis pigmentosa.
Financial Impact
Not specified
Risk Factors
- Preclinical data may not translate to human efficacy.
- No funding or clinical development timeline committed for epilepsy program.
- Company's primary focus remains ophthalmology; pipeline expansion is exploratory.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001372514-26-000063 |
| Exhibit: ex991-pressreleasejune1820.htm | 0001372514-26-000063 |
| Document: 0001372514-26-000063-index-headers.html | 0001372514-26-000063 |
| Document: 0001372514-26-000063-index.html | 0001372514-26-000063 |
| Document: 0001372514-26-000063.txt | 0001372514-26-000063 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 7w ago | 8-K | $2.51 $2.50 | ▼ −0.40% | ▼ −2.37% | $2.27 (−9.59%) |
Aug 19, 2026 9w ago | 8-K | $2.60 $2.67 | ▲ +2.69% | ▲ +4.64% | $2.27 (−12.72%) |
Aug 7, 2026 11w ago | 8-K | $2.64 $2.55 | ▼ −3.41% | ▼ −3.01% | $2.27 (−14.04%) |
Jun 18, 2026 18w ago | 8-K | $2.53 $2.55 | ▲ +0.79% | ▲ +0.26% | $2.27 (−10.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers